PLG101 / PhiloGene - LARVOL DELTA

Targeting CD8+ T cells in cardiovascular diseases - current options and therapeutic perspectives. (PubMed, Cardiovasc Res) - "As a result, the time is ripe to evaluate these treatments in humans. Preclinical development of the first therapeutic anti-CD8 mAb (PLG101) is currently underway."

IO biomarker • Journal • Atherosclerosis • Cardiovascular • Congestive Heart Failure • Heart Failure • Infectious Disease • Inflammation • Ischemic stroke • Oncology • CD8

First-in-class anti-human CD8a monoclonal antibody (PLG-101) to prevent ischemic heart failure (CVCT USA 2024) - No abstract available

Cardiovascular • Congestive Heart Failure • Heart Failure • CD8